TNBC, defined as no estrogen receptor (ER), no progesterone receptor (PR), and no human epidermal growth factor receptor-2 (HER2), accounts for 15–20% of all breast cancer (BC), but is much more problematic than other molecular subtypes of breast tumors and has a poor prognosis [1–3]. This evidence concerns the gene ERBB2 and breast neoplasm.